H. Lundbeck A/S will on 30 August 2007 file an increase of its share
capital by DKK 662,375, nominal value, with the Danish Commerce and
Companies Agency as a result of employees exercising warrants. The
registered share capital will subsequently amount to DKK
1,036,398,155 divided into 207,279,631 shares of DKK 5 each. The
subscription price was DKK 108.11 per share. The new shares shall
carry a right to dividend for the financial year 2007 from the time
of registration of the capital increase, provided that it is decided
on the annual general meeting of the company to pay a dividend for
that financial year.
On 9 December 2003 (see release no. 118), the Supervisory Board of H.
Lundbeck A/S resolved to grant warrants to members of the Executive
Management and key employees of the company and its non-US
subsidiaries. In that connection, the company granted 2,554,092
warrants.
The employees can exercise the warrants in a number of exercise
periods until 30 August 2007. The latest exercise period commenced on
16 August 2007 and closed on 27 August 2007. In respect of the latest
exercise period, two capital increases will be filed, the second of
which will be made 30 August 2007. The first filing was made 22
August 2007, see release no. 285 of 21 August 2007.
The share capital has been increased by DKK 2,045,010 in total as a
result of employees exercising warrants in the latest exercise
period. The exercised warrants constitute approximately 16 per cent
of the total grant of warrants.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79 +45 36 43 26 38
+1 201 350 0187
________________________
Stock Exchange Release No 289 - 30 August 2007
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
